Chronic kidney disease (CKD) is estimated to affect ~13% of the U.S. adult population and will require most healthcare professionals to be aware of management techniques. From stage 1 CKD, where kidney damage may be the only indicator, to stage 5 CKD, where dialysis or a transplant is required, the treatments vary greatly. One of the first systems to be affected by CKD is 1-α hydroxylation of vitamin D by production of the enzyme in the kidney. Alterations in this system contribute to bone disorders that are manifested by mineral changes throughout the course of CKD. This report provides insight on the dietary components and contributions to mineral and bone disorder of CKD and recommendations for treatment when CKD treatment does not require dialysis or transplantation.
CoreshJAstorBGreeneTEknoyanGLeveyA. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
2.
CoreshJSelvinEStevensL. Prevalence of chronic kidney disease in the United States. J Am Med Assn. 2007;298:2038-2047.
3.
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation. Am J Kidney Dis. 2002;39:S1-S266.
ErvinRWangCWrightJKennedy-StephensonJ. Dietary intake of selected minerals for the United States population: 1999-2000. Adv Data. 2004;341:1-8.
9.
FrenchMRVernace-InserraFHawkerGA. A prospective study to identify factors affecting adherence to recommended daily calcium intake in women with low bone mineral density. Am J Clin Nutr. 2008;27:88-95.
10.
TussingLChapman-NovakofskiK. Osteoporosis prevention education: behavior theories and calcium intake. J Am Diet Assoc. 2005;105:92-97.
11.
BurtisWGayLInsognaKEllisonABroadusA. Dietary hypercalciuria in patients with calcium oxalate kidney stones. Am J Clin Nutr. 1994;60:424-429.
12.
KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-S201.
13.
MoeSDruekeTBlockG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-S130.
14.
LemannJJ. Calcium and phosphate metabolism: an overview in health and in calcium stone formers. In: CoeFFavusMPakCParksJPremingerG, eds. Kidney Stones: Medical and Surgical Management. Philadelphia, PA: Lippincott-Raven; 1996:259-288.
15.
GutierrezOIsakovaTRheeE. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205-2215.
16.
DanzigerJ. The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant. 2008;23:2733-2737.
17.
FerrariSLBonjourJ-PRizzoliR. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90:1519-1524.
BurnettS-aMGunawardeneSCBringhurstFRJuppnerHLeeHFinkelsteinJS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006;21:1187-1196.
20.
LarssonTNisbethULjunggrenOJuppnerHJonssonKB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272-2279.
21.
IsakovaTGutierrezOMSmithK. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2011;26:584-591.
22.
FulgoniVRNichollsJReedA. Dairy consumption and related nutrient intake in African-American adults and children in the United States: continuing survey of food intakes by individuals 1994-1996, 1998, and the National Health and Nutrition Examination Survey 1999-2000. J Am Diet Assoc. 2007;107:256-264.
23.
Protein and amino acids. In: Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients): A Report of the Panel on Macronutrients, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Washington, DC: National Academies Press; 2005:589-768.
24.
Krebs-SmithSMGuentherPMSubarAFKirkpatrickSIDoddKW. Americans do not meet federal dietary recommendations. J Nutr. 2010;140:1832-1838.
25.
BeniniOD’AlessandroCGianfaldoniDCupistiA. Extra-phosphate load from food additives in commonly eaten foods: a real and insidious danger for renal patients. J Ren Nutr. 2010Nov3. [Epub ahead of print]
26.
Murphy-GutekunstL. Hidden phosphorus in popular beverages: part 1. J Ren Nutr. 2005;15:e1-e6.
27.
Murphy-GutekunstLBarnesK. Hidden phosphorus at breakfast: part 2. J Ren Nutr. 2005;15:e1-e6.
28.
Murphy-GutekunstLUribarriJ. Hidden phosphorus-enhanced meats: part 3. J Ren Nutr. 2005;15:e1-e4.
29.
SaxL. The Institute of Medicine’s “Dietary reference intake” for phosphorus: a critical perspective. J Am Coll Nutr. 2001;20:271-278.
30.
KemiVEKarkkainenMUMLamberg-AllardtCJE. High phosphorus intakes acutely and negatively affect Ca and bone metabolism in a dose-depentdent manner in healthy young females. Br J Nutr. 2006;96:545-552.
31.
KemiVEKarkkainenMUMKarpHJLaitinenKaELamberg-AllardtCJE. Increased calcium intake does not completely counteract the effects of increased phosphorus intake on bone: an acute dose-response study in healthy females. Br J Nutr. 2008;99:832-839.
32.
SteenbockHBlackA. Fat-soluble vitamins: XVII. The induction of growth-promoting and calcifying properties in a ration by exposure to ultra-violet light. J Biol Chem. 1924;61:405-422.
33.
HessAUngerL. The cure of infantile rickets by artificial light and by sunlight. Proc Soc Exp Biol Med. 1921;18:298.
34.
Recommended Dietary Allowances. Washington, DC: National Research Council; 1968.
35.
Recommended Dietary Allowances. Washington, DC: National Research Council; 1980.
36.
CannellJHollisBZasloffMHeaneyR. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother. 2008;9:107-118.
37.
Bischoff-FerrariHGiovannucciEWillettWDietrichTDawson-HughesB. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18-28.
38.
ShepherdACassACarlsonCRayL. Development and internal validation of a male osteoporosis risk estimation score. Ann Fam Med. 2007;5:540-546.
39.
MartinsDWolfMPanD. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167:1159-1165.
40.
PattersonKPhillipsKHorstR. Vitamin D content and variability in fluid milks from a US Department of Agriculture nationwide sampling to update values in the National Nutrient Database for Standard Reference. J Dairy Sci. 2010;93:5082-5090.
41.
Calcijex [package insert]. North Chicago, IL: Abbott Laboratories; 2007.
LiamisGMilionisHJElisafM. A review of drug-induced hypocalcemia. J Bone Miner Metab. 2009;27:635-642.
44.
PettySO’BrienTWarkJ. Anti-epileptic medication and bone health. Osteoporos Int. 2007;18:129-142.
45.
AlbaTSusaMFukumoriSHashimotoY. The effects of culture conditions on CYP3A4 and MDR1 mRNA induction by 1alpha,25-dihydroxyvitamin D(3) in human intestinal cell lines, Caco-2 and LS180. Drug Metab Pharmacokinet. 2005;20:268-274.
46.
TeucherBDaintyJRSpinksCA. Sodium and bone health: impact of moderately high and low salt intakes on calcium metabolism in postmenopausal women. J Bone Miner Res. 2008;23:1477-1485.
47.
TuckerKL. Osteoporosis prevention and nutrition. Curr Osteoporos Rep. 2009;7:111-117.
48.
CohenAJRoeF. Review of risk factors for osteoporosis with particular reference to a possible aetiological role of dietary salt. Food Chem Toxicol. 2000;38:237-253.
49.
MoeSMDruekeTLameireNEknoyanG. Chronic kidney disease—mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007;14:3-12.
50.
GaberAOMooreLWSukiWJonesSLKnightRJBassBL. Change in glomerular filtration rate as a predictor of surgical outcomes [abstract]. In: American College of Surgeons 96th Annual Clinical Congress. Washington, DC: American College of Surgeons; 2010.
51.
DrosteLHernandezJHolmesCMahdjoubiM. Recommendations for the Diagnosis and Management of Vitamin D Deficiency in Adults. 2009. http://www.guideline.gov/content.aspx?id=14868. Accessed February 28, 2011.
IshaniAPaudelMTaylorB. Renal function and rate of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Osteoporos Int. 2008;19:1549-1556.
54.
LehmannGOttUKammererDSchutzeJWolfG. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3-5. Clin Nephrol. 2008;70:296-306.
55.
LaclairREHellmanRNKarpSL. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005;45:1026-1033.
56.
SchillerLSanta AnaCSheikhMEmmettMFordtranJ. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med. 1989;320:1110-1113.
57.
DaugirdasJTFinnWFEmmettMChertowGM; The Frequent Hemodialysis Network Trial Group. The phosphate binder equivalent dose. Semin Dial. 2011;24:41-49.
58.
PhosLo [package insert]. Waltham, MA: Fresenius Medical Care; 2007.
59.
BurkeSSlatopolskyEGoldbergD. Renagel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997;12:1640-1644.
60.
MartinPWangPRobinsonA. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. Am J Kidney Dis. 2011;57:700-706.
61.
HowPMasonDArrudaJLauA. Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers. Clin Nephrol. 2010;73:370-373.
